Attention: Mr W Bertrand General CounselConfidentiality Agreement • May 3rd, 2007 • AstraZeneca Biopharmaceuticals Inc. • Biological products, (no disgnostic substances)
It has been agreed that it may be appropriate to facilitate transition for AstraZeneca PLC (the Company) and its affiliates to disclose to you confidential data concerning the Company and its affiliates.
EXECUTION VERSIONFacility Agreement • May 31st, 2007 • AstraZeneca Biopharmaceuticals Inc. • Biological products, (no disgnostic substances)
$15,000,000,000 FACILITY AGREEMENT dated 1 May 2007 (as amended on 31 May 2007) for ASTRAZENECA PLC as Borrower arranged by CITIGROUP GLOBAL MARKETS LIMITED DEUTSCHE BANK AG, LONDON BRANCH HSBC BANK PLC and JPMORGAN CAZENOVE LIMITED with HSBC BANK PLC acting as Facility Agent and HSBC BANK USA, NATIONAL ASSOCIATION acting as Swingline Agent _____________________________________________ $15,000,000,000 FACILITY AGREEMENT INCORPORATING A US$ SWINGLINE FACILITY _____________________________________________
EXECUTION VERSIONAmendment Agreement • May 31st, 2007 • AstraZeneca Biopharmaceuticals Inc. • Biological products, (no disgnostic substances)
AMENDMENT AGREEMENT dated 31 MAY 2007 for ASTRAZENECA PLC the Borrower arranged by CITIGROUP GLOBAL MARKETS LIMITED DEUTSCHE BANK AG, LONDON BRANCH HSBC BANK PLC AND JPMORGAN CAZENOVE LIMITED WITH HSBC BANK PLC acting as Facility Agent And HSBC BANK USA, NATIONAL ASSOCIATION acting as Swingline Agent ______________________________________________
FACILITY AGREEMENT dated 1 May 2007 for ASTRAZENECA PLC as Borrower arranged by CITIGROUP GLOBAL MARKETS LIMITED DEUTSCHE BANK AG, LONDON BRANCH and HSBC BANK PLC with HSBC BANK PLC acting as Agent $15,000,000,000 FACILITY AGREEMENTFacility Agreement • May 3rd, 2007 • AstraZeneca Biopharmaceuticals Inc. • Biological products, (no disgnostic substances)
